



**Essential Role of Lysophosphatidylcholine Acyltransferase 3
in the Induction of Macrophage Polarization in PMA-Treated
U937 Cells**

Journal:	<i>Journal of Cellular Biochemistry</i>
Manuscript ID:	Draft
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Taniguchi, Kosuke; Kyushu Dental University, Division of Infections and Molecular Biology, Department of Health Promotion Hikiji, Hisako; Kyushu Dental University, Department of Oral Functional Management Okinaga, Toshinori; Kyushu Dental University, Division of Infections and Molecular Biology, Department of Health Promotion Hashidate-Yoshida, Tomomi; National Center for Global Health and Medicine, Department of Lipid Signaling, Research Institute Shindou, Hideo; National Center for Global Health and Medicine, Department of Lipid Signaling, Research Institute Ariyoshi, Wataru; Kyushu Dental University, Division of Infections and Molecular Biology, Department of Health Promotion Shimizu, Takao; National Center for Global Health and Medicine, Department of Lipid Signaling, Research Institute; The University of Tokyo, Department of Biochemistry and Molecular Biology (Lipidomics), Faculty of Medicine Tominaga, Kazuhiro; Kyushu Dental University, Division of Oral and Maxillofacial Surgery, Department of Science of Physical Function Nishihara, Tatsuji; Kyushu Dental University, Division of Infections and Molecular Biology, Department of Health Promotion</p>
Keywords:	lysophosphatidylcholine acyltransferase 3, macrophage polarization, U937 cells

SCHOLARONE™
Manuscripts

1 Essential Role of Lysophosphatidylcholine Acyltransferase 3 in the Induction of
2 Macrophage Polarization in PMA-Treated U937 Cells
3
4 Kosuke Taniguchi,^{1,2} Hisako Hikiji,^{3*} Toshinori Okinaga,¹ Tomomi
5 Hashidate-Yoshida,⁴ Hideo Shindou,^{4,5} Wataru Ariyoshi,¹ Takao Shimizu,^{4,6} Kazuhiro
6 Tominaga,² and Tatsuji Nishihara¹

7
8 ¹Division of Infections and Molecular Biology, Department of Health Promotion,
9 Kyushu Dental University, Kitakyushu, Fukuoka 803-8580, Japan

10 ²Division of Oral and Maxillofacial Surgery, Department of Science of Physical
11 Function, Kyushu Dental University, Kitakyushu, Fukuoka 803-8580, Japan

12 ³Department of Oral Functional Management, Kyushu Dental University, Kitakyushu,
13 Fukuoka 803-8580, Japan

14 ⁴Department of Lipid Signaling, Research Institute, National Center for Global Health
15 and Medicine, Tokyo 162-8655, Japan

16 ⁵CREST, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012,
17 Japan

18 ⁶Department of Biochemistry and Molecular Biology (Lipidomics), Faculty of
19 Medicine, The University of Tokyo, 113-0033, Japan

20
21 *Running head:* LPCAT3 regulates M1M2-macrophage polarization

22
23 * Correspondence to: Hisako Hikiji, D.D.S., Ph.D., Department of Oral Functional
24 Management, Kyushu Dental University, 2-6-1 Manazuru, Kokurakita-ku, Kitakyushu,

1
2
3
4
5 25 Fukuoka 803-8580, Japan;
6

7 26 Tel: +81-93-582-1131;
8

9 27 Fax: +81-93-582-6000
10

11 28 
12

13 29
14

15
16 30 **Keywords:**
17

18 • lysophosphatidylcholine acyltransferase 3;
19

20 • macrophage polarization;
21

22 • U937 cells
23
24

25 34
26

27 35 Total number of figures: 7
28

29 36 Total number of tables: 1
30
31

32 37
33

34 38
35

36 39 **Grant information**
37

38 40 Contract grant sponsor: Ministry of Education, Culture, Sports, Science and Technology
39

40 41 of Japan; Contract grant number: 23390467 (H.H.), 23792149 (T.O.), 24659841 (T.N.),
41

42 42 24229003 (T.S.), 26460380 (H.S.), and 26870879 (T.H.-Y.)
43
44

45 43
46

47 44
48

49 45
50
51
52
53
54
55
56
57
58
59
60

46 **Abbreviations**

47

48 CXCL10, C-X-C motif ligand 10;

49 DMSO, dimethyl sulfoxide;

50 DPPC, dipalmitoyl-phosphatidylcholine;

51 ELISA, enzyme-linked immunosorbent assay;

52 ER, endoplasmic reticulum;

53 FBS, fetal bovine serum;

54 IFN- γ , interferon- γ ;55 IL-1 β , interleukin-1 β ;

56 IL-1ra, interleukin-1 receptor antagonist;

57 IL-4, interleukin-4;

58 LC-MS, liquid chromatography-mass spectrometry;

59 LPC, lysophosphatidylcholine;

60 LPCATs, lysophosphatidylcholine acyltransferases;

61 LPLATs, lysophospholipid acyltransferases;

62 LPS, lipopolysaccharide;

63 NF- κ B, nuclear factor-kappa-B;

64 PAPC, palmitoyl-arachidonoyl-phosphatidylcholine;

65 PC, phosphatidylcholine;

66 PDPC, palmitoyl-docosahexaenoyl-phosphatidylcholine;

67 PLPC, palmitoyl-linoleoyl-phosphatidylcholine;

68 PMA, phorbol 12-myristate 13-acetate;

69 POPC, palmitoyl-oleoyl-phosphatidylcholine;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 70 SDS, sodium dodecyl sulfate;
- 71 siRNA, small interfering RNA;
- 72 TGF- β , transforming growth factor- β ;
- 73 TNF- α , tumor necrosis factor- α .
- 74
- 75

TO
FOR
PRO
M

76 **Abstract**

77

78 Lysophospholipid acyltransferases (LPLATs) regulate the diversification of fatty
79 acid composition in biological membranes. Lysophosphatidylcholine acyltransferases
80 (LPCATs) are members of the LPLATs that play a role in inflammatory responses. M1
81 macrophages differentiate in response to lipopolysaccharide (LPS) and are
82 pro-inflammatory, whereas M2 macrophages, which differentiate in response to
83 interleukin-4 (IL-4), are anti-inflammatory and involved in homeostasis and wound
84 healing. In the present study, we showed that LPCATs play an important role in
85 M1/M2-macrophage polarization. LPS changed the shape of PMA-treated U937 cells
86 from rounded to spindle shaped and upregulated the mRNA and protein expression of
87 the M1 macrophage markers CXCL10, TNF- α , and IL-1 β . IL-4 had no effect on the
88 shape of PMA-treated U937 cells and upregulated the M2 macrophage markers CD206,
89 IL-1ra, and TGF- β in PMA-treated U937 cells. These results suggest that LPS and IL-4
90 promote the differentiation of PMA-treated U937 cells into M1- and M2-polarized
91 macrophages, respectively. LPS significantly downregulated the mRNA expression of
92 LPCAT3, one of four LPCAT isoforms, and suppressed its enzymatic activity toward
93 linoleoyl-CoA and arachidonoyl-CoA in U937 cells. LPCAT3 knockdown induced a
94 spindle-shaped morphology typical of M1-polarized macrophages, and increased the
95 secretion of CXCL10 and decreased the levels of CD206 in IL-4-activated U937 cells.
96 This indicates that knockdown of LPCAT3 shifts the differentiation of PMA-treated
97 U937 cells from M2- to M1-polarized macrophages. Our findings suggest that LPCAT3
98 plays an important role in M1/M2-macrophage polarization, providing novel potential
99 therapeutic targets for the regulation of immune and inflammatory disorders.

1
2
3
4
5 100 **Introduction**
6
7
8 101

9
10 102 Glycerophospholipids are the major phospholipids in biological membranes and
11
12 103 play an important role as the precursors of lipid mediators, including eicosanoids
13
14 104 (Ishibashi et al., 2013), lysophospholipids (Kremer et al., 2010) and platelet-activating
15
16 105 factor (PAF) (Snyder, 1989) (Ishii and Shimizu, 2000) in the inflammatory response.
17
18 106 Glycerophospholipids are synthesized from glycerol-3-phosphate in the *de novo*
19
20 107 pathway (Kennedy pathway) (Kennedy and Weiss, 1956) and mature in the remodeling
21
22 108 pathway called Lands' cycle (Lands, 1958). In these processes, the recently identified
23
24 109 lysophospholipid acyltransferases (LPLATs) play a major role in the configuration of
25
26 110 the cellular membrane (Shindou et al., 2009) (Harayama et al., 2014). Through these
27
28 111 pathways, phospholipids acquire diversity and asymmetry (*sn*-1 vs *sn*-2) by reacylation
29
30 112 and deacylation reactions catalyzed by LPLATs and phospholipases A₂s, respectively.
31
32
33

34 113 Lysophosphatidylcholine acyltransferases (LPCATs), which are members of
35
36 114 LPLATs, are localized in the endoplasmic reticulum (ER) of many cell types and
37
38 115 incorporate various fatty acids into the *sn*-2 position of lysophosphatidylcholine (LPC)
39
40 116 to produce phosphatidylcholine (PC). Four LPCATs (LPCAT1–4) have been identified
41
42 117 and functionally characterized to date (Shindou et al., 2009) (Hishikawa et al., 2014).
43
44 118 Several studies have shown that LPCATs exert various biological functions. LPCAT1,
45
46 119 which selectively incorporates palmitoyl-CoA into LPC as a substrate in addition to its
47
48 120 involvement in pulmonary surfactant production (Harayama et al., 2014; Nakanishi et
49
50 121 al., 2006), affects the progression of hepatocellular carcinoma (Morita et al., 2013).
51
52 122 LPCAT2 is activated by lipopolysaccharides (LPS) and produces the inflammatory lipid
53
54 123 mediator PAF in mouse peritoneal macrophages (Shindou et al., 2007). LPCAT3, which
55
56
57
58
59
60

1
2
3
4
5 124 preferably incorporates linoleoyl-CoA and arachidonoyl-CoA into LPC (Hishikawa et
6
7 125 al., 2008) (Zhao et al., 2008) (Kazachkov et al., 2008) , upregulates the expression of
8
9 126 peroxisome proliferator-activated receptor γ (PPAR γ) and might be associated with
10
11 127 adipocyte differentiation (Eto et al., 2012). The liver X receptors (LXRs)-LPCAT3
12
13 128 pathway is an important modulator of inflammation (Rong et al., 2013). LPCAT4 is
14
15 129 involved in the deregulation of PC in colorectal cancer (Kurabe et al., 2013).

16
17
18 130 Macrophages are divided into at least two main classes known as M1 and M2
19
20 131 (Solinas et al., 2009). When macrophages are exposed to LPS or interferon- γ (IFN- γ),
21
22 132 they are polarized into M1 macrophages (Mosmann and Coffman, 1989), whereas
23
24 133 exposure to interleukin-4 (IL-4) or IL-13 polarizes the cells into M2 macrophages
25
26 134 (Abramson and Gallin, 1990). M1-polarized macrophages produce pro-inflammatory
27
28 135 cytokines and chemokines, such as tumor necrosis factor- α (TNF- α), interleukin-1 β
29
30 136 (IL-1 β), and C-X-C motif ligand 10 (CXCL10), and infiltrate into injured tissue soon
31
32 137 after damage (Arnold et al., 2007). M2-polarized macrophages, whose markers are
33
34 138 CD206, interleukin-1 receptor antagonist (IL-1ra), and transforming growth factor- β
35
36 139 (TGF- β), are major resident macrophages and appear during the late stages of tissue
37
38 140 repair and remodeling in injured tissue (Biswas and Mantovani, 2012)

39
40
41 141 Macrophages can switch from M1 to M2 or from M2 to M1 phenotypes
42
43 142 according to their microenvironment or in response to certain stimuli (Biswas and
44
45 143 Mantovani, 2012; Gordon and Martinez, 2010; Sica and Mantovani, 2012; Zhang et al.,
46
47 144 2015). Several mechanisms of M1/M2-macrophage polarization have been reported.
48
49 145 The transcription factor nuclear factor-kappa-B (NF- κ B) is a key player in
50
51 146 M1/M2-macrophage polarization (Biswas and Lewis, 2010). M2-polarized macrophages
52
53 147 are epigenetically regulated by histone H3 lysine-4 and histone H3 lysine-27
54
55
56
57
58
59
60

1
2
3
4
5 148 methylation (Ishii et al., 2009). PPAR γ promotes the differentiation of human
6
7 149 monocytes to M2-polarized macrophages (Bouhlef et al., 2007). We speculated that
8
9
10 150 M1/M2-macrophage polarization might be associated with LPCATs, as LPCATs and
11
12 151 M1/M2-polarized macrophages play important roles in inflammatory responses. The
13
14 152 relationship between LPCATs and M1/M2-macrophage polarization has not been
15
16 153 reported to date.

17
18 In the present study, we investigated the physiological role of LPCAT3 in
19
20 154 M1/M2-macrophage polarization and the underlying mechanism using human U937
21
22 155 cells. LPCAT3 mRNA expression was downregulated in LPS-activated U937 cells.
23
24 156 Knockdown of LPCAT3 in U937 cells resulted in a shift from M2- to M1-polarized
25
26 157 macrophages. Our results suggest that LPCAT3 exerts important anti-inflammatory
27
28 158 effects mediated by the suppression of M1-macrophage polarization.
29
30 159
31
32 160

1
2
3
4
5 161 **Materials and methods**
6

7 162

8
9 163 **Reagents**
10

11 164 Recombinant human IL-4 was purchased from R&D Systems (Minneapolis, MN,
12 USA). LPS from *Escherichia coli* 0111:B4 and phorbol 12-myristate 13-acetate (PMA)
13 165 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies and their
14 166 respective sources were as follows: anti-IL-1 β monoclonal antibody (Cell Signaling,
15 167 Beverly, MA, USA), anti-CD206 polyclonal antibody (R&D Systems), anti-IL-1ra
16 168 monoclonal antibody (Santa Cruz Biotechnology, Dallas, TX, USA), anti- β -actin
17 169 monoclonal antibody (Sigma Aldrich), anti-goat IgG (Santa Cruz Biotechnology),
18 170 anti-mouse IgG (GE Healthcare, Little Chalfont, UK). Deuterium-labeled 16:0 LPC,
19 171 16:0-, 18:1-, 18:2-, 20:4-, 22:6-CoA and dilauryl-PC were purchased from Avanti Polar
20 172 Lipid (Alabaster, AL, USA).
21 173
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 175 **Cell culture and differentiation**
39

40 176 Human monocytic leukemia U937 cells (RIKEN, RCB0435) were cultured at
41 177 37°C in a humidified atmosphere of 5% CO₂ in RPMI 1640 supplemented with 10%
42 178 heat-inactivated fetal bovine serum (FBS), 100 units/ml penicillin and 100 μ g/ml
43 179 streptomycin. U937 cells were seeded at a density of 5×10^5 cells/well into 6-well plates
44 180 with RPMI1640 containing 5% FBS and 100 ng/ml PMA. After 12 h of culture, the
45 181 cells were washed with phosphate-buffered saline (PBS, pH 7.2) and incubated with
46 182 LPS (100 ng/ml) or IL-4 (20 ng/ml) for the indicated times.
47
48
49
50
51
52
53
54
55
56
57

58 184 **Morphological characterization and quantification**
59
60

1
2
3
4
5 185 Images of cells were acquired by phase-contrast microscope (Olympus IX71,
6
7 186 Tokyo, Japan). Cells were washed with PBS and further cultured in RPMI 1640
8
9 187 containing 5% FBS for 72 h. The quantification of morphological changes was
10
11 188 performed based on the criteria used in the analysis of neurite outgrowth (Shea and
12
13 189 Beermann, 1994). Cells with more than twice the ratio of major axis to minor axis were
14
15 190 defined as spindle-shaped cells. Spindle-shaped cells were counted in three randomly
16
17 191 selected fields of triplicate cultures. Data are presented as a percentage of the total
18
19 192 number of cells in the field.
20
21
22
23
24

25 194 **Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR)**

26
27 195 Total cellular RNA was extracted with an RNeasy[®] Mini Kit (Qiagen, Valencia,
28
29 196 CA, USA), according to the manufacturer's instructions. cDNA was synthesized with
30
31 197 q-Script[™] cDNA SuperMix reagents (Quanta BioSciences, Gaithersburg, MD, USA).
32
33 198 qRT-PCR analysis was performed by StepOne[™] Real-Time PCR Systems (Applied
34
35 199 Biosystems, Foster City, CA, USA). The reaction for each gene was performed using
36
37 200 Fast SYBR[®] Green Master Mix (Applied Biosystems). Relative quantification was
38
39 201 calculated as a ratio of gene expression to the reference housekeeping gene, 18S rRNA.
40
41 202 The sequences of the primer pairs used in this analysis are presented in Table 1.
42
43
44
45
46
47

48 204 **Phagocytosis assay**

49 205 Macrophage phagocytic activity was quantified using a Phagocytosis Assay Kit,
50
51 206 IgG FITC (Cayman Chemical, Ann Arbor, MI, USA). Briefly, cells were seeded into
52
53 207 6-well plates at a density of 5×10^5 cells/well and treated with PMA (100 ng/ml) for 12
54
55 208 h. The cells were washed twice with PBS and stimulated with LPS or IL-4. After 48 h
56
57
58
59
60

1
2
3
4
5 209 of culture, 100 μ l of the latex beads-rabbit IgG-FITC solution was added to each well.
6
7 210 The cells were incubated for 24 h and then washed twice with PBS to remove the latex
8
9 211 beads. All cells were analyzed using an EPICS XL (Beckman Coulter, Fullerton, CA,
10
11 212 USA). Flow cytometric measurement was performed in the FL-1 channel.
13
14 213

16 214 **Flow cytometry**

18 215 PMA-treated U937 cells (5×10^5 cells) were cultured with IL-4 (20 ng/ml) for 72
20
21 216 h. After washing with PBS supplemented with 1% heat-inactivated FBS and 0.01%
22
23 217 NaN_3 , cells were resuspended in PBS. Cells were then incubated in Clear Back (human
24
25 218 Fc receptor blocking reagent) (MBL, Nagoya, Japan) for 10 min followed by incubation
26
27 219 with FITC-Mouse Anti-Human CD206 (BD Biosciences) for 30 min at room
28
29 220 temperature in the dark. After the final washing step, labeled cells were analyzed by
30
31 221 flow cytometry.
32

36 223 **Western blot analysis**

38 224 Cells were lysed in sodium dodecyl sulfate (SDS) buffer (50 mM Tris-HCl, 2%
39
40 225 SDS; pH 6.8), and the protein concentration of the lysate was measured using a
41
42 226 DC-protein assay kit (Bio-Rad, Hercules, CA, USA). Lysates were boiled at 95°C for 5
43
44 227 min in SDS loading buffer. Electrophoretic separation (10–25 μ g protein/lane) was
45
46 228 carried out on 7.5–15% polyacrylamide gels and then proteins transferred to PVDF
47
48 229 membranes (Millipore, Bedford, MA, USA). The membranes were blocked for 30 min
49
50 230 at room temperature with Blocking One (NACALAI TESQUE, Inc., Kyoto, Japan) and
51
52 231 incubated overnight at 4°C with 0.1% Tween-20 in PBS (PBS-T) containing the
53
54 232 primary antibody. After washing with PBS-T, the membranes were coated with
55
56
57
58
59
60

1
2
3
4
5 233 secondary antibody in PBS for 1 h at room temperature. After washing the membranes
6
7 234 with PBS-T, chemiluminescence detection was performed using ECL reagent
8
9 235 (Amersham Pharmacia Biotech, Uppsala, Sweden). Results were visualized using a
10
11 236 Molecular Imager[®] ChemiDoc[™] XRS Plus system (Bio-Rad). Densitometric analysis
12
13 237 of protein bands was performed using Image Lab[®] (Bio-Rad, Munich, Germany).
14
15 238 Relative expression was calculated by dividing the band intensities of the proteins of
16
17 239 interest by that of β -actin.
18
19
20
21
22

23 **Enzyme-linked immunosorbent assay (ELISA)**

24
25 242 PMA-treated U937 cells (5×10^5 cells) were cultured with or without LPS (100
26
27 243 ng/ml) or IL-4 (20 ng/ml). The supernatants from stimulated U937 cells were collected
28
29 244 at 72 h. The concentrations of CXCL10, TNF- α and TGF- β in the culture supernatants
30
31 245 were determined using an ELISA kit (R&D systems) according to the manufacturer's
32
33 246 instructions.
34
35
36
37

38 **Protein preparation and measurement of LPCAT activity**

39
40 249 U937 cells were scraped into 1 ml of ice-cold buffer containing 20 mM Tris-HCl
41
42 250 (pH 7.4), 300 mM sucrose, and proteinase inhibitor cocktail (Complete, Roche, Basel,
43
44 251 Switzerland). The cells were sonicated on ice three times for 30 seconds using a probe
45
46 252 sonicator (Ohtake Works, Tokyo, Japan). After centrifugation at $9,000 \times g$ for 10 min,
47
48 253 the supernatants were centrifuged at $100,000 \times g$ for 1 h. Resultant pellets were
49
50 254 suspended in buffer containing 20 mM Tris-HCl (pH 7.4), 300 mM sucrose, and 1 mM
51
52 255 EDTA, and protein concentration was measured using the Bio-Rad Protein Assay
53
54 256 (Bio-Rad) with bovine serum albumin as a standard. LPCAT activity was measured
55
56
57
58
59
60

1
2
3
4
5 257 according to Harayama et al. (Harayama et al., 2014). Briefly, 0.01 μ g protein was
6
7 258 added to equal volumes of reaction mixtures containing 200 mM Tris-HCl (pH 7.4), 4
8
9 259 mM CaCl_2 , 2 mM EDTA, 0.03% Tween-20 (Wako Pure Chemical Industries, Osaka,
10
11 260 Japan), 2 μ M each of 16:0-CoA, 18:1-CoA, 18:2-CoA, 20:4-CoA, and 22:6-CoA, and
12
13 261 50 μ M deuterium labeled 16:0 LPC in a total volume of 0.1 ml. After incubation at
14
15 262 37°C for 10 min, reactions were stopped by the addition of 0.3 ml of
16
17 263 chloroform:methanol (1:2, vol/vol) containing dilauryl-phosphatidylcholine as an
18
19 264 internal standard. Total lipids were extracted by the method of Bligh and Dyer (Bligh
20
21 265 and Dyer, 1959) and measured by an Acquity ultra performance liquid chromatography
22
23 266 system (Waters, Milford, MA, USA) and a TSQ Vantage triple stage quadrupole mass
24
25 267 spectrometer (Thermo Fisher Scientific, Waltham, MD, USA) (LC-MS).
26
27
28
29
30

31 269 **Small interfering RNA transfection**

32
33
34 270 Small interfering RNA (siRNA) targeting was used to knockdown LPCAT3
35
36 271 expression in U937 cells. siRNA against human LPCAT3 and siRNA control were
37
38 272 purchased from Santa Cruz Biotechnology. LPCAT3 siRNA consisted of a pool of three
39
40 273 target-specific 19–25 nt siRNAs designed to knock down gene expression. U937 cells
41
42 274 were transfected using Lipofectamine[®] RNAi MAX (Invitrogen, Carlsbad, CA, USA)
43
44 275 according to the manufacturer's instructions. In brief, cells (5×10^5 cells/well) were
45
46 276 seeded into 6-well plates in 2 ml of RPMI supplemented with 5% FBS and treated with
47
48 277 PMA (100 ng/ml) for 12 h. After washing with PBS, the cells were resuspended in 2 ml
49
50 278 of RPMI supplemented with 5% FBS. Lipofectamine[®] RNAi MAX was first diluted in
51
52 279 Opti-MEM (150 μ l; Invitrogen) for 5 min before mixing with an equal volume of
53
54 280 Opti-MEM containing the siRNA (12.5 nM). After 20 min of incubation, 250 μ l of the
55
56
57
58
59
60

1
2
3
4
5 281 resulting RNAiMAX/siRNA was added directly onto the cells. After 24 h of incubation
6
7 282 at 37°C (5% CO₂ atmosphere), the cells were rinsed with 2 ml of RPMI supplemented
8
9 283 with 5% FBS and treated with IL-4 (20 ng/ml).
10
11

12 284

13
14 285 **Statistical analysis**

15
16 286 Statistical analyses were performed using Student's t test (two groups) or
17
18 287 ANOVA (> two groups) followed by post hoc tests, the Tukey-Kramer test. A *P* value
19
20 288 of < 0.05 was considered statistically significant. All statistical calculations were
21
22 289 performed using EZR (Easy R, Saitama Medical Center, Saitama, Japan;
23
24 290 <http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html>), which is based on
25
26 291 R and R commander (Kanda, 2013).
27
28
29
30 292

1
2
3
4
5 293 **Results**
6

7
8 294

9
10 295 **PMA promotes the differentiation of human U937 monocytic cells into**
11
12 296 **macrophage-like cells**

13
14 297 Human U937 monocytic cells are non-adherent cells. After treatment with PMA
15
16 298 (100 ng/ml) for 12 h, U937 cells attached to the culture dish and developed elongated
17
18 299 projections (Fig. 1A). PMA treatment significantly increased the mRNA expression of
19
20 300 the macrophage marker CD68 (Fig. 1B) and the phagocytic activity compared with
21
22 301 those of DMSO-treated U937 cells (Fig. 1C). These results suggest that PMA promotes
23
24 302 the differentiation of U937 cells into macrophage-like cells.
25
26

27 303

28
29 304 **LPS promotes the differentiation of PMA-treated U937 cells into M1-polarized**
30
31 305 **macrophages**

32
33
34 306 LPS changed the shape of PMA-treated U937 cells from rounded to
35
36 307 spindle-shaped (Fig. 2A, *upper left*), whereas IL-4 had no effect (Fig. 2A, *upper right*).
37
38 308 LPS-activated U937 cells showed a significantly higher proportion of spindle-shaped
39
40 309 cells than IL-4-activated U937 cells (Fig. 2A, *lower*). LPS promoted the phagocytic
41
42 310 activity of PMA-treated U937 cells, whereas IL-4 had no effect (Fig. 2B). These results
43
44 311 suggest that PMA-treated U937 cells themselves seem to be polarized into
45
46 312 M2-polarized macrophages and that LPS may induce M1-polarized macrophages in
47
48 313 PMA-treated U937 cells.
49

50
51
52 314 LPS upregulated the mRNA expression of the M1 markers CXCL10, TNF- α ,
53
54 315 and IL-1 β at 12–24 h in PMA-treated U937 cells (Fig. 3A–C, *left*), increased the
55
56 316 secretion of CXCL10 and TNF- α (Fig. 3A and B, *right*), and upregulated the protein
57
58
59
60

1
2
3
4
5 317 expression of IL-1 β at 12–72 h (Fig. 3C, *right*). These results indicate that LPS
6
7 318 promoted M1-polarization of macrophages in PMA-treated U937 cells.
8

9
10 319 In PMA-treated U937 cells, which show certain properties of M2-polarized
11
12 320 macrophages, IL-4 upregulated the mRNA expression of the M2 markers CD206,
13
14 321 IL-1ra, and TGF- β at 24–72 h (Fig. 4A–C, *left*), and upregulated the protein expression
15
16 322 of CD206 and IL-1ra (Fig. 4A, *middle* and 4B, *right*). Flow cytometric analysis showed
17
18 323 that IL-4-activated U937 cells expressed the surface marker CD206 (Fig. 4A, *right*).
19
20 324 However, IL-4 did not affect the secretion of TGF- β (Fig. 4C, *right*), indicating that
21
22 325 IL-4 increased expression of M2-markers, not all, in PMA-treated U937 cells. These
23
24 326 results suggest that IL-4 enhanced M2-polarization in PMA-treated U937 cells, which
25
26 327 were in nature M2-polarized macrophages.
27
28

29
30 328

31 32 329 **LPS downregulates LPCAT3 in PMA-treated U937 cells**

33
34 330 The gene expression profiles of LPCATs in LPS or IL-4-activated U937 cells
35
36 331 were examined by real time qRT-PCR. LPS significantly downregulated the mRNA
37
38 332 expression of LPCAT1, LPCAT2, and LPCAT3 at 12–72 h and that of LPCAT4 at 12 h
39
40 333 in PMA-treated U937 cells (Fig. 5A). The LPS-induced downregulation of LPCAT2 in
41
42 334 U937 cells differed from the previously-reported upregulation of LPCAT2 by LPS in
43
44 335 mouse peritoneal macrophages; this discrepancy could be due to differences between
45
46 336 the U937 cell line and primary macrophages. LPCAT3 mRNA expression in
47
48 337 LPS-activated cells was reduced to one-tenth of that in untreated cells. IL-4 treatment
49
50 338 caused a mild upregulation of LPCAT1 and LPCAT3 mRNA expression at 24–48 h and
51
52 339 of LPCAT4 at 24 h. LPS significantly decreased LPCAT activity toward linoleoyl-CoA
53
54 340 and arachidonoyl-CoA, whereas IL-4 did not (Fig. 5B). Neither LPS nor IL-4 changed
55
56
57
58
59
60

1
2
3
4
5 341 LPCAT activity toward palmitoyl-CoA, oleoyl-CoA, and docosahexaenoyl
6
7 342 (DHA)-CoA.

8
9 343

10
11 344 **Knockdown of LPCAT3 in PMA-treated U937 cells decreases LPCAT activity**
12
13 **toward linoleoyl-CoA and arachidonoyl-CoA**

14
15 346 PMA-treated U937 cells were transfected with control siRNA or LPCAT3 siRNA.
16
17 347 Transfection of LPCAT3 siRNA into PMA-treated U937 cells efficiently
18
19 348 downregulated the mRNA expression of LPCAT3 compared with the control siRNA
20
21 349 (Fig. 6A). LPCAT activities toward linoleoyl-CoA and arachidonoyl-CoA were
22
23 350 significantly decreased in LPCAT3 siRNA-transfected cells (Fig. 6B).

24
25
26
27 351

28
29 352 **Knockdown of LPCAT3 shifts polarization from M2 to M1 in PMA-treated U937**
30
31 **cells**

32
33 354 LPCAT3 siRNA-transfected cells showed a spindle-shaped morphology similar
34
35 355 to that of M1-polarized macrophages, whereas control siRNA-transfected cells showed
36
37 356 a rounded morphology typical of M2-polarized macrophages (Fig. 7A, *left*). LPCAT3
38
39 357 siRNA-transfected cultures had a significantly higher proportion of spindle-shaped cells
40
41 358 than control siRNA-transfected cultures (Fig. 7A, *right*). Analysis of the mRNA and
42
43 359 protein expression of the M1/M2 markers CXCL10 and CD206, which showed the
44
45 360 highest expression among the investigated markers, indicated that LPCAT3 knockdown
46
47 361 significantly increased the secretion of CXCL10, even after the IL-4 induced complete
48
49 362 polarization of PMA-treated U937 cells into M2 macrophages at 48 h (Fig. 7B).
50
51 363 Knockdown of LPCAT3 suppressed the IL-4 induced upregulation of CD206 protein
52
53 364 expression (Fig. 7C). These results suggest that knockdown of LPCAT3 shifts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

365 PMA-treated U937 cells from M2- to M1-polarized macrophages.

For Peer Review

366 **Discussion**

367

368 M1- and M2-polarized macrophages are distinguished by their cellular
369 morphology (Pelegriin and Surprenant, 2009; Zhang et al., 2015), surface antigen
370 presentation, production of cytokines and chemokines (Biswas et al., 2006; Umemura et
371 al., 2008), and phagocytic activity (Vereyken et al., 2011). CXCL10, TNF- α , and IL-1 β
372 are known to be released by M1-polarized macrophages and are referred to as
373 M1-markers (Martinez et al., 2006; Muller-Quernheim et al., 2012). The macrophage
374 mannose receptor CD206, IL-1ra, and TGF- β are anti-inflammatory and
375 M2-macrophage markers. The mRNA and protein expression of CD206 is well known
376 to be potently upregulated by IL-4 stimulation (Porcheray et al., 2005; Stein et al.,
377 1992). However, some studies described that CD206 was not always good marker for
378 human M2-macrophages (Daigneault et al., 2010; Jaguin et al., 2013). To confirm that
379 CD206 is a proper marker of M2-polarized macrophages, we examined the surface
380 expression of CD206 in IL-4-activated U937 cells by flow cytometry (Fig. 4A, *right*).
381 Our results certainly showed that IL-4 increased the expression of CD206 in
382 PMA-treated U937 cells.

383 A previous study suggested that the M1/M2-polarization pattern depends on the
384 characteristics of the tissue microenvironment in U937 cells (Sanchez-Reyes et al.,
385 2014). In the present study, we showed that PMA-treated U937 cells stimulated with
386 LPS and IL-4 are fully polarized to M1- and M2-macrophages, respectively, indicating
387 that M1/M2-macrophage polarization in U937 cells may be a useful model for the
388 investigation of macrophage function. Human monocytic THP-1 cells are reported to
389 differentiate into M2-polarized macrophages in response to PMA treatment (Tjiu et al.,

1
2
3
4
5 390 2009). In the present study, PMA-treated U937 cells showed low levels of CXCL10,
6
7 391 TNF- α , and IL-1 β and the typical cellular morphology and phagocytic activity of
8
9 392 M2-polarized macrophages. These results suggest that PMA-treated U937 cells, which
10
11 393 are in nature polarized toward M2-macrophages, fully shift into M2-polarized
12
13 394 macrophages in response to IL-4.

14
15
16 395 Accumulation of saturated fatty acids, such as palmitic acid, causes lipotoxicity
17
18 396 and induces inflammation, ER stress, and cell death (Ariyama et al., 2010; Prieur et al.,
19
20 397 2011). By contrast, polyunsaturated fatty acids, such as linoleic acid, arachidonic acid
21
22 398 and docosahexaenoic acid, reduce inflammation and ER stress induced by palmitic acid
23
24 399 (Ishiyama et al., 2011; Rong et al., 2013). Furthermore, saturated fatty acids induce the
25
26 400 expression of M1 markers, whereas polyunsaturated fatty acids strongly induce the
27
28 401 expression of M2 markers in adipose tissue macrophages (Prieur et al., 2011).
29
30 402 Sphingolipids, which are one of the essential lipid components of cellular membranes,
31
32 403 regulate the differentiation of monocytes into macrophages in U937 cells (Yamamoto et
33
34 404 al., 2011). LPCAT3 is reported to be a major contributor to increase polyunsaturated
35
36 405 fatty acids, including linoleic acid and arachidonic acid, and is associated with
37
38 406 inflammatory responses in human primary macrophages (Ishibashi et al., 2013).
39
40 407 Therefore, among various LPCATs, LPCAT3 may particularly affect
41
42 408 M1/M2-macrophage polarization associated with inflammation. In the present study, we
43
44 409 showed that LPCAT3 mRNA expression was strongly downregulated and LPCAT
45
46 410 activity toward linoleoyl-CoA and arachidonoyl-CoA was reduced in M1-polarized
47
48 411 macrophages (Fig. 5).

49
50
51
52
53
54 412 Induction of LPCAT3 activity increases the abundance of polyunsaturated PCs
55
56 413 and downregulates the expression of inflammatory mediators such as CXCL10, TNF- α ,

1
2
3
4
5 414 and IL-1 β in mouse primary macrophages. By contrast, knockdown of LPCAT3
6
7 415 decreases the abundance of polyunsaturated PCs and induces inflammatory responses
8
9 416 (Rong et al., 2013). We showed that knockdown of LPCAT3 significantly increased the
10
11 417 secretion of the M1 macrophage marker CXCL10 in PMA-treated U937 cells and
12
13 418 M2-polarized macrophages. In addition, knockdown of LPCAT3 suppressed the
14
15 419 expression of the M2 macrophage marker CD206, even after full M2-polarization by
16
17 420 IL-4 (Fig. 7). Our results suggest that knockdown of LPCAT3 induces a phenotypic
18
19 421 shift from M2- to M1-polarized macrophages.
20
21

22
23 422 Polyunsaturated fatty acids increase membrane fluidity and the flexibility of
24
25 423 cellular membranes (Holzer et al., 2011), whereas excessive contents of saturated fatty
26
27 424 acids reduce membrane fluidity. The decrease in the content of PCs containing linoleic
28
29 425 acid or arachidonic acid in biological membranes caused by the suppression of LPCAT3
30
31 426 may influence membrane fluidity, curvature and function. In fact, LPCAT3 knockdown
32
33 427 in HEK293 cells was reported to have a remarkable effect on cell morphology (Jain et
34
35 428 al., 2009). Therefore, LPCAT3 induced alterations may also cause morphological
36
37 429 changes, such as those of M1-polarized macrophages, in LPCAT3 siRNA-transfected
38
39 430 cells.
40
41

42
43 431 In summary, we showed that modulation of LPCAT3 expression regulates
44
45 432 M1-macrophage polarization. This study supports the development of new
46
47 433 anti-inflammatory drugs capable of altering macrophage phenotypes via the remodeling
48
49 434 pathway of glycerophospholipids.
50

51
52 435
53
54
55
56
57
58
59
60

436 **Acknowledgments**

437

438 This study was supported by JSPS KAKENHI Grant Numbers 23390467 (H.H.),
439 23792149 (T.O.), 24659841 (T.N.), 24229003 (T.S.), 26460380 (H.S.), and 26870879
440 (T.H.-Y.); CREST, JST (H.S.). The Department of Biochemistry and Molecular
441 Biology (Lipidomics), Faculty of Medicine, The University of Tokyo, is financially
442 supported by Shimadzu Corp. and Ono Pharmaceutical Co., Ltd.

FOR
REVIEW

443 **References**

444

445 Abramson SL, Gallin JI. 1990. IL-4 inhibits superoxide production by human
446 mononuclear phagocytes. *the Journal of Immunology* 144(15):625-630.

447 Ariyama H, Kono N, Matsuda S, Inoue T, Arai H. 2010. Decrease in

448 membrane phospholipid unsaturation induces unfolded protein

449 response. *The Journal of biological chemistry* 285(29):22027-22035.

450 Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A,

451 Gherardi RK, Chazaud B. 2007. Inflammatory monocytes recruited

452 after skeletal muscle injury switch into antiinflammatory

453 macrophages to support myogenesis. *The Journal of experimental*

454 *medicine* 204(5):1057-1069.

455 Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B,

456 Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A,

457 Sica A. 2006. A distinct and unique transcriptional program expressed

458 by tumor-associated macrophages (defective NF- κ B and enhanced

459 IRF-3/STAT1 activation). *Blood* 107(5):2112-2122.

460 Biswas SK, Lewis CE. 2010. NF- κ B as a central regulator of macrophage

461 function in tumors. *Journal of leukocyte biology* 88(5):877-884.

462 Biswas SK, Mantovani A. 2012. Orchestration of metabolism by

463 macrophages. *Cell metabolism* 15(4):432-437.

464 Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and

465 purification. *Can J Biochem Physiol* 37(8):911-917.

- 1
2
3
4
5 466 Bouhleb MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S,
6
7 Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi
8
9 G. 2007. PPAR γ activation primes human monocytes into alternative
10
11 M2 macrophages with anti-inflammatory properties. *Cell metabolism*
12
13 469 6(2):137-143.
14
15 470
16
17 471 Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. 2010. The
18
19 472 identification of markers of macrophage differentiation in
20
21 473 PMA-stimulated THP-1 cells and monocyte-derived macrophages.
22
23 474 *PLoS One* 5(1):e8668.
24
25
26 475 Eto M, Shindou H, Koeberle A, Harayama T, Yanagida K, Shimizu T. 2012.
27
28 476 Lysophosphatidylcholine acyltransferase 3 is the key enzyme for
29
30 477 incorporating arachidonic acid into glycerophospholipids during
31
32 478 adipocyte differentiation. *International journal of molecular sciences*
33
34 479 13(12):16267-16280.
35
36
37 480 Gordon S, Martinez FO. 2010. Alternative activation of macrophages:
38
39 481 mechanism and functions. *Immunity* 32(5):593-604.
40
41
42 482 Harayama T, Eto M, Shindou H, Kita Y, Otsubo E, Hishikawa D, Ishii S,
43
44 483 Sakimura K, Mishina M, Shimizu T. 2014. Lysophospholipid
45
46 484 acyltransferases mediate phosphatidylcholine diversification to
47
48 485 achieve the physical properties required in vivo. *Cell metabolism*
49
50 486 20(2):295-305.
51
52
53 487 Hishikawa D, Hashidate T, Shimizu T, Shindou H. 2014. Diversity and
54
55 488 function of membrane glycerophospholipids generated by the
56
57
58
59
60

- 1
2
3
4
5 489 remodeling pathway in mammalian cells. *J Lipid Res* 55(5):799-807.
6
7
8 490 Hishikawa D, Shindou H, Kobayashi S, Nakanishi H, Taguchi R, Shimizu T.
9
10 491 2008. Discovery of a lysophospholipid acyltransferase family essential
11
12 492 for membrane asymmetry and diversity. *Proceedings of the National*
13
14 493 *Academy of Sciences of the United States of America*
15
16 494 105(8):2830-2835.
17
18
19 495 Holzer RG, Park EJ, Li N, Tran H, Chen M, Choi C, Solinas G, Karin M.
20
21 496 2011. Saturated fatty acids induce c-Src clustering within membrane
22
23 497 subdomains, leading to JNK activation. *Cell* 147(1):173-184.
24
25
26 498 Ishibashi M, Varin A, Filomenko R, Lopez T, Athias A, Gambert P, Blache D,
27
28 499 Thomas C, Gautier T, Lagrost L, Masson D. 2013. Liver X receptor
29
30 500 regulates arachidonic acid distribution and eicosanoid release in
31
32 501 human macrophages: a key role for lysophosphatidylcholine
33
34 502 acyltransferase 3. *Arterioscler Thromb Vasc Biol* 33(6):1171-1179.
35
36
37
38 503 Ishii M, Wen H, Corsa CA, Liu T, Coelho AL, Allen RM, Carson WFt,
39
40 504 Cavassani KA, Li X, Lukacs NW, Hogaboam CM, Dou Y, Kunkel SL.
41
42 505 2009. Epigenetic regulation of the alternatively activated macrophage
43
44 506 phenotype. *Blood* 114(15):3244-3254.
45
46
47 507 Ishii S, Shimizu T. 2000. Platelet-activating factor (PAF) receptor and
48
49 508 genetically engineered PAF receptor mutant mice. *Prog Lipid Res*
50
51 509 39(1):41-82.
52
53
54 510 Ishiyama J, Taguchi R, Akasaka Y, Shibata S, Ito M, Nagasawa M,
55
56 511 Murakami K. 2011. Unsaturated FAs prevent palmitate-induced
57
58
59
60

- 1
2
3
4
5 512 LOX-1 induction via inhibition of ER stress in macrophages. *J Lipid*
6
7 513 *Res* 52(2):299-307.
8
9
10 514 Jaguin M, Houlbert N, Fardel O, Lecureur V. 2013. Polarization profiles of
11
12 515 human M-CSF-generated macrophages and comparison of
13
14 516 M1-markers in classically activated macrophages from GM-CSF and
15
16 517 M-CSF origin. *Cellular immunology* 281(1):51-61.
18
19 518 Jain S, Zhang X, Khandelwal PJ, Saunders AJ, Cummings BS, Oelkers P.
20
21 519 2009. Characterization of human lysophospholipid acyltransferase 3.
22
23 520 *J Lipid Res* 50(8):1563-1570.
24
25
26 521 Kanda Y. 2013. Investigation of the freely available easy-to-use software
27
28 522 'EZR' for medical statistics. *Bone marrow transplantation*
29
30 523 48(3):452-458.
31
32
33 524 Kazachkov M, Chen Q, Wang L, Zou J. 2008. Substrate preferences of a
34
35 525 lysophosphatidylcholine acyltransferase highlight its role in
36
37 526 phospholipid remodeling. *Lipids* 43(10):895-902.
38
39
40 527 Kennedy EP, Weiss SB. 1956. The function of cytidine coenzymes in the
41
42 528 biosynthesis of phospholipids. *The Journal of biological chemistry*
43
44 529 222(1):193-214.
45
46
47 530 Kremer AE, Martens JJ, Kulik W, Rueff F, Kuiper EM, van Buuren HR, van
48
49 531 Erpecum KJ, Kondrackiene J, Prieto J, Rust C, Geenes VL,
50
51 532 Williamson C, Moolenaar WH, Beuers U, Oude Elferink RP. 2010.
52
53 533 Lysophosphatidic acid is a potential mediator of cholestatic pruritus.
54
55 534 *Gastroenterology* 139(3):1008-1018.
56
57
58
59
60

- 1
2
3
4
5 535 Kurabe N, Hayasaka T, Ogawa M, Masaki N, Ide Y, Waki M, Nakamura T,
6
7 536 Kurachi K, Kahyo T, Shinmura K, Midorikawa Y, Sugiyama Y, Setou
8
9
10 537 M, Sugimura H. 2013. Accumulated phosphatidylcholine (16:0/16:1) in
11
12 538 human colorectal cancer: possible involvement of LPCAT4. *Cancer*
13
14 539 *science* 104(10):1295-1302.
- 15
16
17 540 Lands WEM. 1958. Metabolism of glycerolipides: a comparison of lecithin
18
19 541 and triglyceride synthesis. *The Journal of biological chemistry*
20
21 542 231(2):883-888.
- 22
23
24 543 Martinez FO, Gordon S, Locati M, Mantovani A. 2006. Transcriptional
25
26 544 profiling of the human monocyte-to-macrophage differentiation and
27
28 545 polarization: new molecules and patterns of gene expression. *The*
29
30 546 *Journal of Immunology* 177(10):7303-7311.
- 31
32
33 547 Morita Y, Sakaguchi T, Ikegami K, Goto-Inoue N, Hayasaka T, Hang VT,
34
35 548 Tanaka H, Harada T, Shibasaki Y, Suzuki A, Fukumoto K, Inaba K,
36
37 549 Murakami M, Setou M, Konno H. 2013. Lysophosphatidylcholine
38
39 550 acyltransferase 1 altered phospholipid composition and regulated
40
41 551 hepatoma progression. *Journal of hepatology* 59(2):292-299.
- 42
43
44 552 Mosmann TR, Coffman RL. 1989. TH1 and TH2 cells: different patterns of
45
46 553 lymphokine secretion lead to different functional properties. *Ann Rev*
47
48 554 *Immunol* 7:145-173.
- 49
50
51 555 Muller-Quernheim UC, Potthast L, Muller-Quernheim J, Zissel G. 2012.
52
53 556 Tumor-cell co-culture induced alternative activation of macrophages is
54
55 557 modulated by interferons in vitro. *Journal of interferon & cytokine*

- 1
2
3
4
5 558 research : the official journal of the International Society for
6
7 559 Interferon and Cytokine Research 32(4):169-177.
8
9
10 560 Nakanishi H, Shindou H, Hishikawa D, Harayama T, Ogasawara R, Suwabe
11
12 561 A, Taguchi R, Shimizu T. 2006. Cloning and characterization of mouse
13
14 562 lung-type acyl-CoA:lysophosphatidylcholine acyltransferase 1
15
16 563 (LPCAT1). Expression in alveolar type II cells and possible
17
18 564 involvement in surfactant production. The Journal of biological
19
20 565 chemistry 281(29):20140-20147.
21
22
23 566 Pelegrin P, Surprenant A. 2009. Dynamics of macrophage polarization reveal
24
25 567 new mechanism to inhibit IL-1beta release through pyrophosphates.
26
27 568 The EMBO journal 28(14):2114-2127.
28
29
30 569 Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet
31
32 570 N, Dormont D, Gras G. 2005. Macrophage activation switching: an
33
34 571 asset for the resolution of inflammation. Clin Exp Immunol
35
36 572 142(3):481-489.
37
38
39 573 Prieur X, Mok CYL, Velagapudi VR, Núñez V, Fuentes L, Montaner D,
40
41 574 Ishikawa K, Camacho A, Barbarroja N, O'Rahilly S, Sethi JK, Dopazo
42
43 575 J, Oresic M, Ricote M, Vidal-Puig A. 2011. Differential lipid
44
45 576 partitioning between adipocytes and tissue macrophages modulates
46
47 577 macrophage lipotoxicity and M2/M1 polarization in obese mice.
48
49 578 Diabetes 60(3):797-809.
50
51
52 579 Rong X, Albert CJ, Hong C, Duerr MA, Chamberlain BT, Tarling EJ, Ito A,
53
54 580 Gao J, Wang B, Edwards PA, Jung ME, Ford DA, Tontonoz P. 2013.

- 1
2
3
4
5 581 LXR_s regulate ER stress and inflammation through dynamic
6
7 582 modulation of membrane phospholipid composition. *Cell metabolism*
8
9
10 583 18(5):685-697.
- 11
12 584 Sanchez-Reyes K, Bravo-Cuellar A, Hernandez-Flores G, Lerma-Diaz JM,
13
14 585 Jave-Suarez LF, Gomez-Lomeli P, de Celis R, Aguilar-Lemarrooy A,
15
16 586 Dominguez-Rodriguez JR, Ortiz-Lazareno PC. 2014. Cervical cancer
17
18 587 cell supernatants induce a phenotypic switch from U937-derived
19
20 588 macrophage-activated M1 state into M2-like suppressor phenotype
21
22 589 with change in Toll-like receptor profile. *BioMed research*
23
24 590 international 2014:683068.
- 25
26
27
28 591 Shea TB, Beermann ML. 1994. Respective roles of neurofilaments,
29
30 592 microtubules, MAP1B, and tau in neurite outgrowth and stabilization.
31
32 593 *Mol Biol Cell* 5(8):863-875.
- 33
34
35 594 Shindou H, Hishikawa D, Harayama T, Yuki K, Shimizu T. 2009. Recent
36
37 595 progress on acyl CoA: lysophospholipid acyltransferase research. *J*
38
39 596 *Lipid Res* 50 Suppl:S46-51.
- 40
41
42 597 Shindou H, Hishikawa D, Nakanishi H, Harayama T, Ishii S, Taguchi R,
43
44 598 Shimizu T. 2007. A single enzyme catalyzes both platelet-activating
45
46 599 factor production and membrane biogenesis of inflammatory cells.
47
48 600 Cloning and characterization of acetyl-CoA:Lyso-PAF
49
50 601 acetyltransferase. *The Journal of biological chemistry*
51
52 602 282(9):6532-6539.
- 53
54
55
56 603 Sica A, Mantovani A. 2012. Macrophage plasticity and polarization: in vivo
57
58
59
60

- 1
2
3
4
5 604 veritas. The Journal of clinical investigation 122(3):787-795.
6
7
8 605 Snyder F. 1989. Biochemistry of platelet-activating factor: a unique class of
9
10 606 biologically active phospholipids. Proc Soc Exp Biol Med
11
12 607 190(2):125-135.
13
14 608 Solinas G, Germano G, Mantovani A, Allavena P. 2009. Tumor-associated
15
16 609 macrophages (TAM) as major players of the cancer-related
17
18 610 inflammation. Journal of leukocyte biology 86(5):1065-1073.
19
20
21 611 Stein M, Keshav S, Harris N, Gordon S. 1992. Interleukin 4 potentially
22
23 612 enhances murine macrophage mannose receptor activity: a marker of
24
25 613 alternative immunologic macrophage activation. The Journal of
26
27 614 experimental medicine 176(1):287-292.
28
29
30
31 615 Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC,
32
33 616 Dai YS, Inoue H, Yang PC, Kuo ML, Jee SH. 2009. Tumor-associated
34
35 617 macrophage-induced invasion and angiogenesis of human basal cell
36
37 618 carcinoma cells by cyclooxygenase-2 induction. The Journal of
38
39 619 investigative dermatology 129(4):1016-1025.
40
41
42 620 Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang GF, Okada
43
44 621 M, Balazs M, Adany R, Shibata T, Takami T. 2008. Tumor-infiltrating
45
46 622 myeloid-derived suppressor cells are pleiotropic-inflamed
47
48 623 monocytes/macrophages that bear M1- and M2-type characteristics.
49
50 624 Journal of leukocyte biology 83(5):1136-1144.
51
52
53
54 625 Vereyken EJ, Heijnen PD, Baron W, de Vries EH, Dijkstra CD, Teunissen
55
56 626 CE. 2011. Classically and alternatively activated bone marrow derived
57
58
59
60

- 1
2
3
4
5 627 macrophages differ in cytoskeletal functions and migration towards
6
7
8 628 specific CNS cell types. *Journal of neuroinflammation* 8:58.
9
10 629 Yamamoto H, Naito Y, Okano M, Kanazawa T, Takematsu H, Kozutsumi Y.
11
12 630 2011. Sphingosylphosphorylcholine and lysosulfatide have inverse
13
14 631 regulatory functions in monocytic cell differentiation into
15
16 632 macrophages. *Arch Biochem Biophys* 506(1):83-91.
17
18 633 Zhang F, Liu H, Jiang G, Wang H, Wang X, Wang H, Fang R, Cai S, Du J.
19
20
21 634 2015. Changes in the proteomic profile during the differential
22
23 635 polarization status of the human monocyte-derived macrophage
24
25 636 THP-1 cell line. *Proteomics* 15(4):773-786.
26
27 637 Zhao Y, Chen YQ, Bonacci TM, Bredt DS, Li S, Bensch WR, Moller DE,
28
29
30 638 Kowala M, Konrad RJ, Cao G. 2008. Identification and
31
32 639 characterization of a major liver lysophosphatidylcholine
33
34 640 acyltransferase. *The Journal of biological chemistry*
35
36 641 283(13):8258-8265.
37
38
39 642
40
41
42 643

1
2
3
4
5 644 **Figure legends**
6
7

8 645

9
10 646 **Fig. 1 PMA promotes the differentiation of human U937 monocytic cells into**
11
12 647 **macrophage-like cells**

13
14 648 U937 cells (5×10^5 cells/well) were seeded into 6-well plates and treated with DMSO
15
16 649 or PMA (100 ng/ml) for 12 h.

17
18 650 A: Representative images of DMSO-treated U937 cells (DMSO) and PMA-treated
19
20 651 U937 cells (PMA). Scale bar = 50 μ m.

21
22
23 652 B: The mRNA expression of the macrophage differentiation marker CD68 was analyzed
24
25 653 by quantitative real-time PCR. Data are presented as the mean \pm SD of three
26
27 654 independent experiments. * $p < 0.01$ vs. DMSO.

28
29 655 C: Phagocytic activity was measured by flow cytometry. Filled and unfilled histograms
30
31 656 represent DMSO-treated U937 cells (DMSO) and PMA-treated U937 cells (PMA),
32
33 657 respectively. The experiment was performed three times. Similar results were obtained
34
35 658 for each experiment and a representative histogram is shown.
36
37

38
39 659

40
41 660 **Fig. 2 LPS and IL-4 alter the morphology and function of PMA-treated U937**
42
43 661 **cells**

44
45 662 U937 cells (5×10^5 cells/well) were seeded into 6-well plates and treated with PMA
46
47 663 (100 ng/ml) for 12 h. After washing with PBS, the samples were stimulated with LPS
48
49 664 (100 ng/ml) or IL-4 (20 ng/ml) for various periods of time (12, 24, 48 and 72 h).

50
51 665 A: Representative images of M1- and M2-polarized macrophages (*upper*). Scale bar =
52
53 666 50 μ m. The percentage of spindle-shaped cells (positive cells) was quantified as
54
55 667 described in the materials and methods section (*lower*). * $p < 0.01$ vs. IL-4.
56
57
58
59
60

1
2
3
4
5 668 B: Phagocytic activity was measured by flow cytometry. Filled, black, red and blue
6
7 669 histograms represent DMSO-treated U937 cells (DMSO), PMA-treated U937 cells
8
9 670 (Control), LPS-activated U937 cells (LPS) and IL-4-activated U937 cells (IL-4),
10
11 671 respectively. The experiment was performed three times. Similar results were obtained
12
13 672 for each experiment and a representative histogram is shown.
14
15
16 673 Data are presented as the mean \pm SD of three independent experiments.
17

674

20
21 675 **Fig. 3 LPS induces the expression of M1 markers**

22
23 676 A, B and C: The mRNA expression of the M1 macrophage markers CXCL10, TNF- α ,
24
25 677 and IL-1 β was analyzed by quantitative real-time PCR. * p < 0.01 vs. LPS at 0 h (*left*
26
27 678 *panels*). The secretion of CXCL10 and TNF- α in culture after 72 h was analyzed by
28
29 679 ELISA. # p < 0.01 vs. control, * p < 0.01 vs. IL-4 (A and B, *right panels*). The protein
30
31 680 expression of IL-1 β was analyzed by western blotting. The experiment was performed
32
33 681 three times. Similar results were obtained for each experiment and a representative
34
35 682 immunoblot is shown (C, *right*).
36
37

683

38
39
40
41 684 **Fig. 4 IL-4 induces the expression of M2 markers**

42
43 685 A, B and C: The expression of M2 macrophage markers CD206, IL-1ra and TGF- β was
44
45 686 analyzed by quantitative real-time PCR. # p < 0.01 vs. IL-4 at 0 h (*left panels*). The
46
47 687 protein expression of CD206 and IL-1ra was analyzed by western blotting. The
48
49 688 experiment was performed three times. Similar results were obtained for each
50
51 689 experiment and representative immunoblots are shown (A, *middle* and B, *right panels*).
52
53 690 CD206 membrane expression was measured by flow cytometry. Filled and black
54
55 691 histograms represented DMSO-treated U937 cells (DMSO) and IL-4-activated U937
56
57
58
59
60

1
2
3
4
5 692 cells (IL-4), respectively. The experiment was performed three times. Similar results
6
7 693 were obtained for each experiment and a representative histogram is shown (A, right).
8
9 694 The secretion of TGF- β in culture after 72 h was analyzed by ELISA (C, right).
10
11
12 695

13
14 696 **Fig. 5 LPS significantly decreases the mRNA expression of LPCATs and their**
15
16 697 **enzymatic activities**

17
18 698 A: The mRNA expression of LPCAT1, LPCAT2, LPCAT3 and LPCAT4 was analyzed
19
20 699 by quantitative real-time PCR. * $p < 0.01$ vs. LPS at 0 h. # $p < 0.01$ vs. IL-4 at 0 h.
21
22

23 700 B: LPCAT activity was measured using LC-MS/MS. # $p < 0.01$ vs. control, * $p < 0.01$ vs.
24
25 701 IL-4.
26

27 702 Data are presented as the mean \pm SD of three independent experiments.

28
29 703 DPPC, dipalmitoyl phosphatidylcholine; POPC, palmitoyl oleoyl phosphatidylcholine;
30
31 704 PLPC, palmitoyl linoleoyl phosphatidylcholine; PAPC, palmitoyl arachidonoyl
32
33 705 phosphatidylcholine; PDPC, palmitoyl docosahexaenoyl phosphatidylcholine.
34
35
36 706

37
38 707 **Fig. 6 Knockdown of LPCAT3 in PMA-treated U937 cells decreases LPCAT**
39
40 708 **activity toward linoleoyl-CoA and arachidonoyl-CoA**

41
42 709 U937 cells (5×10^5 cells/well) were seeded into 6-well plates and treated with PMA
43
44 710 (100 ng/ml) for 12 h. After washing with PBS, the samples were transfected with
45
46 711 control siRNA (siControl) and LPCAT3 siRNA (siLPCAT3) using Lipofectamine[®]
47
48 712 RNAi MAX and incubated for 48 h.
49

50
51 713 A: The mRNA expression of LPCAT3 was analyzed by quantitative real-time PCR.
52
53

54 714 B: LPCAT activity was measured using LC-MS/MS.
55

56 715 Data are presented as the mean \pm SD of three independent experiments. * $p < 0.01$ vs.
57
58
59
60

1
2
3
4
5 716 control siRNA-transfected cells.
6
7

8 717

9
10 718 **Fig. 7 Knockdown of LPCAT3 shifts PMA-treated U937 cells from M2- to**
11
12 719 **M1-polarized macrophages**

13
14 720 A: Representative images of control siRNA (siControl) and LPCAT3 siRNA
15
16 721 (siLPCAT3) in PMA-treated U937 cells (*left panels*). Scale bar = 50 μ m. The
17
18 722 percentage of spindle-shaped cells was quantified as described in the materials and
19
20 723 methods section (*right*). * $p < 0.01$ vs. control siRNA-transfected cells.


21
22
23 724 B: U937 cells (5×10^5 cells/well) were seeded into 6-well plates and treated with PMA
24
25 725 (100 ng/ml) for 12 h. After washing with PBS, the samples were transfected with
26
27 726 control siRNA and LPCAT3 siRNA for 24 h. The cells were rinsed with 2 ml of RPMI
28
29 727 supplemented with 5% FBS and then stimulated with or without IL-4 (20 ng/ml) and
30
31 728 incubated for 48 h. The secretion of CXCL10 was analyzed by ELISA. Data are
32
33 729 presented as the mean \pm SD of three independent experiments. * $p < 0.01$ vs. control
34
35 730 siRNA-transfected cells with IL-4 at 48 h.

36
37
38 731 C: CD206 protein expression was analyzed by western blotting. The experiment was
39
40 732 performed three times. Similar results were obtained for each experiment and a
41
42 733 representative immunoblot is shown. Band intensity levels were normalized to β -actin.
43
44 734 Data are presented as the mean \pm SD of three independent experiments. * $p < 0.01$ vs.
45
46 735 LPCAT3 siRNA-transfected cells stimulated with IL-4.

47
48
49
50 736
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Fig. 1



190x254mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Fig. 2



190x254mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Fig. 3



190x254mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Fig. 4



190x254mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Fig. 5



190x254mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Fig. 6



190x254mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Fig. 7



190x254mm (300 x 300 DPI)

Table 1. The sequences of the primer pairs used in this analysis are indicated.

Name	Sense primer, 5'→3'	Antisense primer, 5'→3'
18S rRNA	CGAACGTCTGCCCTATCAACTT	ACCCGTGGTCACCATGGTA
CD68	AGGCTGTGGGTGGGATCA	CTTGGAAAGGAGGAAATGAAAGTC
CXCL10	TTCCTGCAAGCCAATTTTGTC	TCTTCTCACCCCTTCTTTTTCATTGT
CD206	CGCTACTAGGCAATGCCAATG	GCAATCTGCGTACCACTTGTTTT
TNF- α	GCAGGTCTACTTTGGGATCATTG	GCGTTTGGGAAGGTTGGA
IL-1 β	TCAGCCAATCTTCATIGCTCAA	TGGCGAGCTCAGGTACTTCTG
TGF- β	CGCGTGCTAATGGTGGAAA	GCTGTGTGTACTCTGCTTGAACCTGT
IL-1ra	CTGCACAGCGATGGAAGCT	GCCTTCGTCAGGCATATTGG
LPCAT1	TTGCTCCAATTCGTGTCTTATT	ATCCATTGAAAAGAACATAGCA
LPCAT2	CCTCATGACACTGACGCTCTC	CAGGAAGTCCACAACCTTCCTC
LPCAT3	CATTGCCTCATTCAACATCAACA	AGGAATTCATCTGGAAGCAGAC
LPCAT4	AAGGTGGCGTTGGAACCA	CCCAGCCTCCGAAGCA